Department of Ophthalmology, Enshi Huiyi Eye Hospital.
Department of Laboratory, Enshi Huiyi Medical Laboratory, Hubei, China.
Medicine (Baltimore). 2021 May 14;100(19):e25684. doi: 10.1097/MD.0000000000025684.
There is no review or meta-analysis to compare the efficacy and safety of methotrexate plus anti-vascular endothelial growth factor (anti-VEGF) therapy in patients with diabetic macular edema (DME). It is worthy to critically review the evidence of the assessment of combined therapies to inform clinical practice. Therefore, the purpose of this study was to compare the efficacy and safety of methotrexate plus anti-VEGF therapy in the treatment of DME and to provide evidence for clinical practice.
The electronic databases of EMBASE, PubMed, Cochrane Library, and Web of Science were searched from the inception to April 2021 using the following key terms: "diabetic macular edema," "methotrexate," and "anti-vascular endothelial growth factor," for all relevant studies. Additionally, the reference lists from published original articles and relevant reviews were assessed to identify more relevant studies. Only English publications were included. Data were extracted by review of each study for population, mean age, gender, follow-up duration, study design, publishing date, characteristics, and outcomes assessment. The present study was performed using Review Manager (RevMan Version 5.3, The Cochrane Collaboration, Copenhagen, Denmark).
We hypothesized that combined therapies would provide better therapeutic benefits compared to single method.
10.17605/OSF.IO/APD6 V.
目前尚无综述或荟萃分析比较甲氨蝶呤联合抗血管内皮生长因子(anti-VEGF)治疗糖尿病黄斑水肿(DME)的疗效和安全性。批判性地评估联合治疗的评估证据以指导临床实践是值得的。因此,本研究旨在比较甲氨蝶呤联合抗 VEGF 治疗 DME 的疗效和安全性,为临床实践提供证据。
检索 EMBASE、PubMed、Cochrane 图书馆和 Web of Science 电子数据库,从建库至 2021 年 4 月,使用以下关键词:“糖尿病黄斑水肿”、“甲氨蝶呤”和“抗血管内皮生长因子”,以检索所有相关研究。此外,还评估了已发表原始文章和相关综述的参考文献列表,以确定更多相关研究。仅纳入英文出版物。通过对每项研究的人群、平均年龄、性别、随访时间、研究设计、发表日期、特征和结局评估进行审查来提取数据。本研究采用 Review Manager(RevMan Version 5.3,The Cochrane Collaboration,Copenhagen,Denmark)进行。
我们假设联合治疗与单一方法相比会提供更好的治疗效果。
OSF 注册号:10.17605/OSF.IO/APD6 V.